|
RESEARCH METHODOLOGY ISSUES |
PMI1 |
|
SELF-REPORT OF HEALTH-RELATED LOST PRODUCTIVE TIME AT WORK: BIAS AND THE OPTIMAL RECALL PERIOD
Stewart WF, Ricci J, Leotta CR, Chee E, AdvancePCS, Hunt Valley, MD, USA |
| PMI2 |
| SMOOTHED BOOTSTRAP FOR CONFIDENCE INTERVAL FOR COST-EFFECTIVENESS RATIOS
Lenne X, Lebrun T, CRESGE-LABORES, LILLE, France |
| PMI3 |
| INCORPORATING CLINICAL LEVEL-OF-EVIDENCE CRITERIA INTO A BREAST CANCER TREATMENT MODEL FOR JAPAN
Becker R1, Noe L1, Gore M2, Chen D1, 1Ovation Research Group, Highland Park, IL, USA; 2Avalon Health Solutions, Philadelphia, PA, USA |
| PMI4 |
| MARKOV MODELLING TO CONVERT TRIAL-BASED COST-EFFECTIVENESS INFORMATION TO OTHER COUNTRIES; THE TIOTROPIUM EXAMPLE
Oostenbrink JB, Rutten-van Mölken MP, Institute for Medical Technology Assessment, Rotterdam, Netherlands |
| PMI5 |
| A PROBLEM WITH STOCHASTIC ECONOMIC EVALUATION WHEN THE TIME HORIZONS FOR THE COST AND EFFECTIVENESS MEASUREMENTS ARE ASYMMETRICAL
Backhouse M1, Bell T2, 1Research Triangle Institute, Manchester, UK; 2Research Triangle Institute, Raleigh-Durham, NC, USA |
| PMI6 |
| ESTIMATING AND COMPARING RESOURCE USE AND COST OF G-CSF USE IN CHEMOTHERAPY WITH THE ACTIVITY-BASED COSTING (ABC) METHOD IN 3 SETTINGS
Annemans LJ1, Vanoverbeke N2, Caekelbergh K2, Van Belle S3, Cocquyt V3, Standaert B4, 1Ghent University, HEDM, MEISE, Belgium; 2HEDM, MEISE, Belgium; 3Ghent University Hospital, GENT, Belgium; 4Amgen Inc, Brussels, Belgium |
| PMI7 |
| PROBABILISTIC SENSITIVITY ANALYSIS FOR EVALUATING COST-UTILITY OF ENTACAPONE TREATMENT FOR PARKINSON'S DISEASE
Linna M, National Research and Development Centre for Welfare and Health, Helsinki, Finland |
| PMI8 |
| DO HEALTH CARE PURCHASERS PREFER PAYING FOR LIFE EXTENSION OR QUALITY OF LIFE IMPROVEMENT?
Kerrigan J, Knight C, Heron Evidence Development Ltd, Stevenage, UK |
| PMI9 |
| USE OF AN AUTOMATED PROCESS TO SCAN AND INTERPRET MANUALLY-CODED DATA FORMS IN PHARMACOECONOMICS RESEARCH
Reardon G1, Mozaffari E2, 1RxI Associates, Worthington, OH, USA; 2Pharmacia Corporation, Kalamazoo, MI, USA |
| PMI10 |
| THE 'NICE' APPROACH TO PHARMACOECONOMICS: AN ECONOMICS PERSPECTIVE
Birch S, Gafni A, McMaster University, Hamilton, ON, Canada |
| PMI11 |
| FEASIBILITY OF A DATABASE APPROACH TO ADHERENCE WITH OSTEOPOROSIS THERAPY
Garfield FB1, Caro JJ1, Naujoks C2, 1Caro Research Institute, Concord, MA, USA; 2Novartis Pharma AG, Basel, Switzerland |
| PMI12 |
| CAREGIVER-BURDEN MEASURES IN ALZHEIMER'S DISEASE: A COMPREHENSIVE REVIEW
Borenstein J1, Chang S2, Cohen A2, Reyes E1, Russak SM1, Chiou CF3, 1Cedars-Sinai Health System, Zynx Health Incorporated, Beverly Hills, CA, USA; 2Novartis Pharmaceutical Corporation, East Hanover, NJ, USA; 3Zynx Health Inc.-a subsidiary of Cedars-Sinai Health System, Beverly Hills, CA, USA |
| PMI13 |
| A COMPARISON OF EQ-5D TIME TRADE-OFF VALUES OBTAINED IN GERMANY, UK AND SPAIN: COULD THERE BE ONE EUROPEAN EQ TARIFF?
Busschbach JJ, Erasmus University, Rotterdam, Netherlands |
| PMI14 |
| TO TRANSLATE OR TO ADAPT - WHAT DO THE QUESTIONS MEAN?
Doward LC, McKenna SP, Whalley D, Galen Research, Manchester, UK |
| PMI15 |
| COST ANALYSIS FOR END-OF-LIFE CARE
Hanlon JT, Smith D, Fendrick AM, University of Michigan, Ann Arbor, MI, USA |
| PMI16 |
| VALUATION OF INFORMAL CARE
van den Berg B, Erasmus University Rotterdam, Rotterdam, Netherlands |
| PMI17 |
| THE RELEVANCE OF A COST IMPLICATION ASSESSMENT BEFORE CLINICAL TRIAL COMPLETION FOR ECONOMIC MODEL DEVELOPMENT: THE EXAMPLE OF THE RESPECT STUDY (RISK EVALUATION AND STROKE PREVENTION IN THE ELDERLY CERIVASTATIN TRIAL)
Klever-Deichert G1, Mast O2, Lauterbach K1, 1University of Cologne, Cologne, Germany; 2Bayer Vital GmbH & Co KG, Leverkusen, Germany |
| PMI18 |
| MODELING ANTIBIOTIC EFFICACY BY INFECTIOUS AGENT AND PROBABILITY OF RESISTANCE
Dombeck M1, Earnshaw S1, Candrilli S1, Xuan J2, Bakst A2, Kirsch JM3, 1RTI Health Solutions, Research Triangle Park, NC, USA; 2GlaxoSmithKline, Collegeville, PA, USA; 3GlaxoSmithKline, Harlow, United Kingdom |
| PMI19 |
| COST-EFFECTIVENESS OF TUBERCULOSIS PREVENTIVE THERAPY IN HIV-INFECTED PATIENTS: STUDY OF MISSING VARIABLES
Chakrabarti A, Sikkim Manipal Institute of Medical Sciences, Gangtok, India |
| PMI20 |
| A REAL OPTION APPROACH TO VALUING PHARMACEUTICAL INVESTMENTS AND FIRMS
Cassimon D, Engelen PJ, University of Antwerp, Antwerpen, Belgium |
| PMI21 |
| ESTIMATING INFLUENZA-RELATED EXCESS HOSPITAL ADMISSIONS
Scuffham P1, Piercy J2, 1York University, York, UK; 2Mapi Values, Macclesfield, UK |
| PMI22 |
| MICE (MODULE FOR STANDARDISED INDIRECT COST ESTIMATION) INCREASES THE TRANSFERABILITY OF STUDY RESULTS
Welte R1, Jager J1, Leidl R2, 1National Institute of Public Health and the Environment, Bilthoven, The Netherlands, 2University of Ulm, Ulm, Germany |
| PMI23 |
| CHANGING STRATEGIES IN THE PROMOTION OF HEALTH CARE RESEARCH IN GERMANY
Walshe R, Glossmann JP, Waldschmidt DT, Reis A, Diehl V, University of Cologne, Cologne, Germany |
| PMI24 |
| QUALITY OF LIFE: FUNCTIONING OR NEED FULFILMENT?
McKenna SP, Whalley D, Doward LC, Galen Research, Manchester, UK |
| PMI25 |
| THE RELATION OF DISTRIBUTION- AND ANCHOR-BASED APPROACHES ON INTERPRETATION OF CHANGES IN HEALTH-RELATED QUALITY OF LIFE
Norman GR, Gwadry-Sridhar FH, Guyatt GH, Walter SD, McMaster University, Hamilton, ON, Canada |
| PMI26 |
| ASSESSMENT OF RESPONDENT ACCEPTABILITY OF UTILITY MEASURES: DISCRIMINATORY POWER OF GRAPHIC POSITIONING SCALE VERSUS TRADITIONAL SCALING MEASURES
Franic DM1, Pathak DS2, 1The University of Georgia, Athens, GA, USA; 2The Ohio State University, Columbus, OH, USA |
| PMI27 |
|
FACTORS INFLUENCING COMPLETION OF THE EUROQOL EQ-5D GENERIC QOL QUESTIONNAIRE
Hazell ML, Cropper JA, Frank TL, Frank PI, North West Lung Research Centre, Manchester, UK |
 |
|
CANCER |
| PCN1 |
| BASELINE ANEMIA AND RISK OF POOR RESPONSE TO CHEMOTHERAPY IN INTERMEDIATE GRADE NON-HODGKIN'S LYMPHOMA (IGNHL) PATIENTS
Lawless G, Gupta S, Tannous RE, Amgen, Inc, Thousand Oaks, CA, USA |
| PCN2 |
| COST OF TREATMENT AND FOLLOW UP OF BREAST CANCER. A RETROSPECTIVE EVALUATION IN A COMPREHENSIVE CANCER CENTRE
Lilliu H1, Morel J1, Brun C2, Berlie J3, 1Clp-santé, Paris, France; 2Novartis Pharma, RUEIL MALMAISON, France; 3Centre René Huguenin, SAINT CLOUD, France |
| PCN3 |
| USING LEVEL OF EVIDENCE CRITERIA IN THE EVALUATION OF PHARMACOECONOMIC RESULTS
Becker R1, Noe L1, Gore M2, Chen D1, 1Ovation Research Group, Highland Park, IL, 2 Avalon Health Solutions, Philadelphia, PA |
| PCN4 |
| COST-EFFECTIVENESS OF URATE OXIDASE IN PREVENTION AND TREATMENT OF SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES
Moeremans K1, Annemans LJ2, 1HEDM, Meise, Belgium; 2Ghent University, HEDM, MEISE, Belgium |
| PCN5 |
| FIRST-LINE THERAPY FOR ADVANCED BREAST CANCER-COST-EFFECTIVENESS OF ANASTROZOLE VERSUS TAMOXIFEN
Marchetti M1, Liberato N2, Barosi G1, 1IRCCS Policlinico San Matteo, Pavia, Italy; 2Civil Hospital, Voghera. Italy, Pavia, Italy |
| PCN6 |
| MODELLING THE COST-EFFECTIVENESS OF DOCETAXEL IN THE SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)
Sharplin P1, Bose UK1, Holmes J2, 1Aventis Pharma UK, West Malling, Kent, UK; 2EAG, London, UK |
| PCN7 |
| COST OF THE POST-PBPC-REINFUSION PERIOD IN HIGH DOSE TREATMENT OF NON-HODGKIN'S FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM
Van Kriekinge G1, Coiffier B2, Witz B3, Erder HM4, Standaert B1, 1Amgen Inc, Brussels, Belgium; 2Centre Hospitalier Lyon Sud, Pierre Bénite, France; 3Hôpital Brabois, Vandoeuvre les Nancy, France; 4Amgen Inc, Thousand Oaks, CA, USA |
| PCN8 |
| COST OF MANAGING SEVERE HYPERURICEMIA AND TUMOUR LYSIS SYNDROME IN HAEMATOLOGIC MALIGNANCIES
Annemans LJ1, Moeremans K2, 1Ghent University, HEDM, MEISE, Belgium; 2HEDM, Meise, Belgium |
| PCN9 |
| COST-EFFECTIVENESS OF IMAGE-GUIDED VERSUS BLIND INSERTION OF HICKMAN LINES IN ADULT CANCER PATIENTS BY NURSES
Boland A1, Fitzsimmons L2, Haycox A1, 1University of Liverpool, Liverpool, UK; 2Christie Hospital NHS Trust, Manchester, UK |
| PCN10 |
| COST OF HOSPITALIZATION FOR THORACIC SURGERY IN PATIENTS WITH LUNG CANCER IN GREECE
Leftakis A1, Geitona M2, 1Thoracic Diseases SOTIRIA Hospital, Athens, Greece; 2National School of Public Health, Athens, Greece |
| PCN11 |
| COST-EFFECTIVENESS OF SENTINEL LYMPH NODE MAPPING AND ADJUVANT INTERFERON THERAPY FOR STAGE II MELANOMA
Wilson LS, Reyes CM, Lu C, Lu M, Yen C, University of California San Francisco, San Francisco, CA, USA |
| PCN12 |
| THE RELATIONSHIP OF AGE AND DURATION OF HORMONAL THERAPY USE AMONG PATIENTS DIAGNOSED WITH CANCER OF THE PROSTATE
Stolshek B1, Hersom K2, Pelletier E2, Delgado D1, 1Amgen, Inc, Thousand Oaks, CA, 2The Lewin Group, San Francisco, CA |
| PCN13 |
| PHARMACOECONOMIC ANALYSIS OF ADVANCED NON-SMALL CELL LUNG CANCER TREATMENT WITH DOCETAXEL-CISPLATIN, PACLITAXEL-CISPLATIN AND PACLITAXEL-CARBOPLATIN
Rubio Terrés C1, Tisaire JL1, Kobina S2, Moyano A3, 1Aventis Pharma, S.A, Madrid, Spain; 2Aventis Pharma, Bridgewater, NJ, USA; 3Hospital Ramón y Cajal, Madrid, Spain |
| PCN14 |
| CHEMOTHERAPY-INDUCED NEUROPATHY IN OVARIAN CANCER COST EFFECTIVENESS
Hay JW, Patel BV, University of Southern California, Los Angeles, CA, USA |
| PCN15 |
| QOL CHANGE OVER TIME POST-REINFUSION OF PBPC IN HIGH DOSE TREATMENT OF NON-HODGKIN'S FOLLICULAR LYMPHOMA (N-HFL) WITH AND WITHOUT FILGRASTIM USE
Van Kriekinge G1, Coiffier B2, Witz B3, Erder HM4, Standaert B1, 1Amgen Inc, Brussels, Belgium; 2Centre Hospitalier Lyon Sud, Pierre Bénite, France; 3Hópital Brabois, Vandoeuvre les Nancy, France; 4Amgen Inc, Thousand Oaks, CA, USA |
| PCN16 |
| ELAPSED TIME TO DISCLOSURE OF BRCA1/2 GENETIC TESTING RESULTS AND PARTICIPANTS' DISTRESS: PRELIMINARY FINDINGS FROM A RESEARCH SETTING
Dorval M1, Maunsell E1, Morel S1, Dugas MJ2, Simard JR1, 1Université Laval, Québec, QC, Canada; 2Concordia University, Montréal, QC, Canada |
| PCN17 |
| PSYCHOMETRIC PROPERTIES OF THE EORTC QUALITY OF LIFE CORE QUESTIONNAIRE (QLQ-C30) IN EORTC TRIALS
Collins G1, Bottomley A1, Fayers P2, de Graeff A3, Groenvold M4, Petersen M4, Aaronson NK5, Sprangers M6, 1European Organisation for the Research and Treatment of Cancer, Brussels, Belgium; 2Aberdeen University, Aberdeen, Belgium; 3University Medical Centre, Utrecht, Utrecht, Netherlands; 4Bispebjerg Hospital, Copenhagen, Denmark; 5Netherlands Cancer Institute, Netherlands; 6University of Amsterdam, Netherlands |
| PCN18 |
| QUALITY OF LIFE IN CANCER CLINICAL TRIALS- AN OVERVIEW OF APPROACHES WITHIN THE EORTC
Bottomley A, European Organisation for Research and Treatment of Cancer (EORTC), Quality of Life Unit, Brussels, Belgium |
| PCN19 |
| CHOICE OF OPTIMAL ANTI-EMETIC STRATEGIES IN CANCER THERAPY
Hartmann M, University of Jena, Jena, Germany |
|
|
|
INFECTIOUS DISEASE |
| PIN1 |
| IMPACT OF INFLUENZA AND TREATMENT WITH OSELTAMIVIR ON INDIVIDUALS' DAILY ACTIVITIES AND RETURN TO NORMAL ACTIVITY
Gyldmark M1, Barker C2, Garrison L3, 1F. Hoffman-La Roche Ltd, Basel, Switzerland; 2Hoffmann La Roche, Palo Alto, CA, USA; 3Roche Pharmaceuticals, Palo Alto, CA, USA |
| PIN2 |
| COST-EFFECTIVENESS OF HIV-SCREENING OF PATIENTS ATTENDING A CLINIC FOR SEXUALLY TRANSMITTED DISEASES IN AMSTERDAM
Bos J1, Fennema JSA2, Postma MJ1, 1Groningen University Institute for Drug Exploration (GUIDE), Groningen, Netherlands; 2Municipal Health Service, Amsterdam, Netherlands |
| PIN3 |
| THE IMPACT OF DRUG COMPLIANCE ON THE COST OF TREATING HIV/AIDS IN AFRICA
Becker R, Shakur U, Ovation Research Group, Highland Park, IL, USA |
| PIN4 |
| A RETROSPECTIVE ANALYSIS OF TREATMENT PATTERNS AND COSTS IN EXTERNAL GENITAL WARTS FOR THE NETHERLANDS
van der Meijden W1, Notowicz A2, Blog F2, Langley P3, 1AZR Dijkzigt, Rotterdam, Netherlands; 2Medisch Centrum Haaglanden / Westeinde, The Hague, Netherlands; 33M Pharmaceuticals, St Paul, MN, USA |
| PIN5 |
| COST-UTILITY ANALYSIS OF A PNEUMOCOCCAL/MENINGOCOCCAL COMBINATION VACCINE FOR INFANTS
Welte R1, Bos J2, Rümke H3, Postma M2, Jager J1, van den Dobbelsteen G1, van Alphen L1, 1National Institute of Public Health and the Environment, Bilthoven, Netherlands; 2Groningen University Institute for Drug Exploration (GUIDE), Groningen, Netherlands; 3Vaccine Centre of the Erasmus University, Rotterdam, Netherlands |
| PIN6 |
| ESTIMATED COSTS TO CONDUCT A PHASE III CLINICAL TRIAL OF A NEW PULMONARY TUBERCULOSIS DRUG
Dombeck M1, Dennett SL2, Hamilton CD3, Bell L1, 1RTI Health Solutions, Research Triangle Park, NC, 2Eli Lilly and Company, Indianapolis, IN, 3Duke University, Durham, NC |
| PIN7 |
| PHARMACOECONOMIC EVALUATION OF IMIQUIMOD (ALDARAÔ) FOR THE TREATMENT OF EXTERNAL GENITAL WARTS IN A DUTCH TREATMENT ENVIRONMENT
Langley P1, Salden P2, Nuijten M3, 13M Pharmaceuticals, St Paul, MN, USA; 23M Pharma, Zoeterwoude, Netherlands; 3Medtap International, Jisp, Netherlands |
| PIN8 |
| A COST-BENEFIT ANALYSIS OF INFLUENZA VACCINATION IN A COMPANY IN ITALY (ENI SPA)
Colombo GL, S.A.V.E. - Economic eValuations Analyses Studies, Milano, Italy |
| PIN9 |
| COST-BENEFIT ANALYSIS OF VACCINATING HEALTHY WORKING ADULTS AGAINST INFLUENZA IN THE NETHERLANDS
Jansema P1, van Genugten ML2, Heijnen MLA2, Jager JC3, Postma MJ1, 1Groningen University, Groningen, Netherlands; 2National Institute of Public Health and the Environment, Bilthoven, Netherlands; 3National Institute of Public Health and the Environment, Bilthoven, Netherlands |
| PIN10 |
| EUROPEAN PHARMACOECONOMIC MODEL: THE ONYCHOTREE STUDY
Baron F1, Hamel-Gariépy L2, Arnould B1, Gupta AK3, 1Mapi Values, LYON, France; 2Galderma, Paris - La Défense, France; 3Sunnybrook and Women's College Health Sciences Centre, London, ON, Canada |
| PIN11 |
| A COST BENEFIT ANALYSIS OF TWO ALTERNATIVE MASS IMMUNIZATION PROGRAMS WITH A CONJUGATE VACCINE AGAINST MENINGOCCOCAL DISEASE TYPE C
Simons WR1, Rancourt C2, Grégoire JP2, Dostie A2, 1Global Health Economics and Outcomes Research Inc, Short Hills, NJ, USA; 2Merck Frosst Canada Ltd, Kirkland, QC, Canada |
| PIN12 |
|
BURDEN OF ILLNESS IMPOSED BY SEVERE SEPSIS IN GERMANY
Schmid A1, Burchardi H2, Schneider H1, Clouth J3, 1HealthEcon AG, Basel, Switzerland; 2Goettingen University, Goettingen, Germany; 3Lilly Deutschland, Bad Homburg, Germany |
| PIN13 |
| CAN VARICELLA BE ELIMINATED BY UNIVERAL CHILDHOOD VACCINATION COST-BENEFICIALLY? - EXAMPLES FOR EUROPE
Goertz A1, Banz K2, Wagenpfeil S3, Neiss A3, Wutzler P4, Bisanz H1, Fischer-Hauck A1, Klose T1, 1GlaxoSmithKline, Munich, Germany; 2Outcomes International, Basel, Switzerland; 3Institute for Medical Statistics and Epidemiology at Technical University Munich, Munich, Germany; 4University of Jena, Jena, Germany |
| PIN14 |
| A STUDY ON THE HEALTH EFFECTS OF FLU AND FLU-LIKE ILLNESSES IN THE WORKING POPULATION AND THEIR COST IMPACT TO A BIG CORPORATION IN HONG KONG
Lee KK, Chan TY, Lau JT, Kwong SK, Lee WS, The Chinese University of Hong Kong, Hong Kong, China |
| PIN15 |
|
ECONOMIC COMPARISON OF SEQUENTIAL (IV TO PO) CIPROFLOXACIN/METRONIDAZOLE VS PIPERACILLIN/TAZOBACTAM FOR THE TREATMENT OF PATIENTS WITH COMPLICATED INTRA-ABDOMINAL INFECTIONS
Gilliland KK1, Paladino JA2, Cohn SM3, 1South Buffalo Mercy Hospital, Buffalo; 2NY University at Buffalo, Amherst, NY; 3University of Miami School of Medicine, Coral Gables, FL. |
| PIN16 |
| COST-EFFECTIVENESS OF TERBINAFINE AND ITRACONAZOLE IN TOENAIL ONYCHOMYCOSIS IN POLAND: MODELLING STUDY WITH THREE-YEAR TIME HORIZON
Orlewska E, Medical University of Warsaw, Warsaw, Poland |
| PIN17 |
| HOW CAN PRODUCTS WITH MARGINAL EFFICACY SAVE MONEY? THE EXAMPLE OF A NON SPECIFIC, IMMUNOSTIMULATING, PREVENTIVE TREATMENT FOR RECURRENT UPPER RESPIRATORY TRACT INFECTIONS IN CHILDREN
Mégas F1, Boulanger P2, Arnould B1, Cozma G3, 1Mapi Values, Lyon, France; 2Zambon, Issy les Moulineaux, France; 3OM Pharma, Geneva, Switzerland |
| PIN18 |
| DIRECT AND INDIRECT COSTS OF RESPIRATORY INFECTIONS
Birnbaum HG1, Greenberg P1, Morley MA1, Colice GL2, 1Analysis Group/Economics, Cambridge, MA, USA; 2Washington Hospital Center, Washington, DC, USA |
| PIN19 |
| POTENTIAL USE OF FLUOROQUINOLONES IN THE TREATMENT OF PULMONARY TUBERCULOSIS
Dombeck M1, Duch D2, Dennett SL3, Bell L1, 1RTI Health Solutions, Research Triangle Park, NC, USA; 2Private Consultant, Raleigh, NC, USA; 3Eli Lilly and Company, Indianapolis, IN, USA |
| PIN20 |
| ESTIMATING THE RETURN ON INVESTMENT FOR TUBERCULOSIS DRUGS
Mauskopf JA, Bell L, Neighbors D, Dombeck M, RTI Health Solutions, Research Triangle Park, NC, USA |
| PIN21 |
| ANTIBIOTIC PROPHYLAXIS IN TOTAL HIP REPLACEMENT SURGERY: ASSESSMENT OF GLOBAL CONFORMITY TO FRENCH GUIDELINES
Bedouch P, Labarère J, Mareau E, Allenet B, Calop J, François P, Grenoble University Hospital, Grenoble, France |
| PIN22 |
| PROPHYLAXIS AGAINST RSV, VARICELLA AND PNEUMOCOCCAL INFECTIONS: ECONOMIC-BASED DECISION-MAKING
Strutton DR, Stang PE, Galt Associates, Sterling, VA, USA |
| PIN23 |
| THE FIRST STEP TO GENERATING UTILITY FROM QUALITY OF LIFE: A COMPARISON OF ITEM PREFERENCES AND ITEM SEVERITY
Doward LC1, Whalley D1, McKenna SP1, Meads DM1, Cook SA1, Langley PC2, 1Galen Research, Manchester, UK; 23M Pharmaceuticals, St Paul, MN, USA |
| PIN24 |
| THE DEVELOPMENT AND VALIDATION OF THE INFLUENZA DAILY DISRUPTION QUESTIONNAIRE (IDDQ)
Wild DJ1, Doll HA1, Gyldmark M2, Hakim Z3, 1Oxford Outcomes, Oxford, UK; 2 F. Hoffman-La Roche Ltd, Basel, Switzerland; 3 F. Hoffman-La Roche Ltd, Palo Alto, CA, USA |
|
|
|
KIDNEY & URINARY DISEASE |
| PKU1 |
| COST-EFFECTIVENESS ANALYSIS OF THREE SURGICAL TREATMENTS FOR FEMALE STRESS URINARY INCONTINENCE
Gao X1, Brooks EA1, Moora C2, Van Wallendael C3, 1PPD Inc, Morrisville, NC, USA; 2Reimbursement Principles, Inc, Littleton, CO, USA; 3SURx Inc, Pleasanton, CA, USA |
| PKU2 |
| AN ECONOMIC MODEL OF UNSTABLE BLADDER IN ITALY
Annoni G1, Corey R2, Bachleda M3, Bentkover J4, Stewart EJ4, Kurth H4, 1Milan-Bicocca University, Milan, Italy, 2University of the Sciences in Philadelphia, Pharmacia Corporation, Peapack, NJ, USA; 3Pharmacia Corporation, Peapack, NJ, USA; 4Innovative Health Solutions, Brookline, MA, USA |
| PKU3 |
| CUMULATIVE INCIDENCE AND TOTAL COSTS ASSOCIATED WITH URINARY AND OVERACTIVE BLADDER DISORDERS IN EMPLOYED POPULATIONS
Muchmore L1, Lynch WD2, Gardner H1, Williamson T3, 1Options and Choices, Inc, Cheyenne, WY, USA; 2William M. Mercer, Incorporated, Denver, CO, USA; 3Pharmacia Corporation, Peapack, NJ, USA |
| PKU4 |
| COST-MINIMISATION STUDY COMPARING SIMULECT VERSUS THYMOGLOBULINE IN RENAL TRANSPLANT INDUCTION
Lilliu H1, Brun C2, Le Pen C3, Priol G1, Reigneau O2, Lebranchu Y4, 1Clp-santé, Paris, France; 2Novartis Pharma, RUEIL MALMAISON, France; 3Université Paris Dauphine, Paris, France; 4CHU Bretonneau, Tours, France |
| PKU5 |
| HEALTH-RELATED CONSEQUENCES AND COSTS OF OVERACTIVE BLADDER
Wagner T1, Hu TW2, Bentkover J3, LeBlanc K3, Piacentini A4, Stewart W4, Corey R5, Zhou Z6, Hunt TL6, On Behalf of TNPRT7, 1Department of Veterans Affairs, Menlo Park, CA, USA; 2University of California, Berkeley, Berkeley, CA, USA; 3Innovative Health Solutions, Brookline, MA, USA; 4Innovative Medical Research, Inc, Towson, MD, USA; 5University of the Sciences in Philadelphia, Pharmacia Corporation, Peapack, NJ, USA; 6Pharmacia Corporation, Peapack, NJ, USA; 7 *, Peapack, NJ, USA |
| PKU6 |
| INTERNATIONAL PSYCHOMETRIC VALIDATION AND CROSS-CULTURAL EQUIVALENCE OF A URINARY INCONTINENCE SPECIFIC QOL SCALE (CONTILIFE®) IN SIX EUROPEAN COUNTRIES
Arnould B1, Laforêt C1, Carita P2, Marquis P1, 1Mapi Values, Lyon, France; 2Sanofi-Synthelabo, Bagneux, France |
|
|
|
MENTAL HEALTH |
| PMH1 |
|
RIGOROUS CRITERIA FOR TREATMENT RESPONSE DIFFERENTIATED EFFICACY OF OLANZAPINE VERSUS HALOPERIDOL IN PATIENTS WITH SCHIZOPHRENIA
Kinon BJ, Zhao Z, Barber BL, Gilmore JA, Lilly Research Laboratories, Indianapolis, IN, USA |
| PMH2 |
| IMPROVEMENT IN QUALITY OF LIFE AND DEPRESSIVE SYMPTOMS IN SCHIZOPHRENIC PATIENTS IS ASSOCIATED WITH ROBUST ACUTE TREATMENT RESPONSE OF OLANZAPINE VERSUS HALOPERIDOL
Kinon BJ, Zhao Z, Barber BL, Gilmore JA, Lilly Research Laboratories, Indianapolis, IN, USA |
| PMH3 |
| PATIENT MEDICATION ATTITUDE AFTER SWITCHING TO ZIPRASIDONE FROM OTHER ANTIPSYCHOTICS
Dugar A1, Awad G2, Voruganti LNP2, 1Pfizer Pharmaceuticals Group, Pfizer, Inc, New York, NY, USA; 2University of Toronto, Toronto, ON, Canada |
| PMH4 |
| DRUG SELECTION, DOSING, AND UTILIZATION PATTERNS AMONG DEPRESSED PATIENTS TREATED WITH SSRI'S AND VENLAFAXINE IN U.S. MANAGED CARE PLANS
Valuck RJ, University of Colorado School of Pharmacy, Denver, CO, USA |
| PMH5 |
| THE COST-EFFECTIVENESS OF QUETIAPINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS PARTIALLY RESPONSIVE TO PREVIOUS ANTIPSYCHOTICS - AN ECONOMIC ANALYSIS OF THE PRIZE STUDY
Tilden D1, Aristides M1, Meddis D1, Burns T4, 1M-TAG Limited, Chatswood, New South Wales, Australia; 2M-TAG Limited, London, UK; 3AstraZeneca, Macclesfield, Cheshire, UK; 4St Georges Hospital Medical School, London, UK |
| PMH6 |
| PATTERNS OF COMORBIDITIES AND COPRESCRIBING AMONG DEPRESSED PATIENTS TREATED WITH SSRI'S AND VENLAFAXINE IN US MANAGED CARE PLANS
Valuck RJ, University of Colorado School of Pharmacy, Denver, CO, USA |
| PMH7 |
| CHANGES IN SCHIZOPHRENIA-RELATED TOTAL DIRECT MEDICAL COSTS FOLLOWING INITIATION OF OLANZAPINE OR RISPERIDONE IN A PRIVATELY INSURED POPULATION IN THE UNITED STATES
Russo P1, Smith MW1, Namjoshi M2, 1The MEDSTAT Group, Washington, DC, USA; 2Lilly Research Laboratories, Indianapolis, IN, USA |
| PMH8 |
| SCHIZOPHRENIA OUTCOMES RESEARCH STUDY IN SPAIN: TOLERABILITY AND ECONOMIC RESULTS WITH ATYPICAL ANTIPSYCHOTICS
Rejas J1, Bobes J2, Garcia-Garcia M3, Rico-Villademoros F3, Madrigal M1, Hernández G1, 1Pfizer S.A, Madrid, Spain; 2University of Oviedo, Oviedo, Spain; 3Biometrica, Barcelona, Spain |
| PMH9 |
| ECONOMIC ANALYSIS OF PATIENTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER
Swensen A1, Claxton A1, Birnbaum HG2, Greenberg P2, Marynchencko M2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis Group/Economics, Cambridge, MA, USA |
| PMH10 |
| MANAGEMENT AND COST OF A MANIC EPISODE IN BIPOLAR DISORDER - A FRENCH STUDY
Levy E1, Olié JP2, 1University Paris-Dauphine, Paris, France; 2Sainte-Anne Hospital, Paris, France |
| PMH11 |
| RETROSPECTIVE ECONOMIC EVALUATION OF MIRTAZAPINE, VENLAFAXINE XR AND SERTRALINE IN A MANAGED CARE POPULATION
Pinto LA1, Wang SW1, Shen Y2, Wiener D1, Armstrong E3, 1Health Benchmarks Inc, Woodland Hills, CA, 2Organon Inc, West Orange, NJ, 3University of Arizona, Tucson, AZ |
| PMH12 |
| THE COST OF TREATING SCHIZOPHRENIA IN ROUTINE CLINICAL PRACTICE: RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA (CNOMSS)
Trakas K1, Lin D2, Balshaw R2, Robinson K1, Andrew E1, 1Janssen-Ortho Inc, Toronto, ON, Canada; 2Syreon Corporation, Vancouver, BC, Canada |
| PMH13 |
| THE DIRECT COST OF RISPERIDONE VERSUS HALOPERIDOL THERAPY OF CHRONIC SCHIZOPHRENIA IN POLAND
Niewada MP, Medical University of Warsaw, Warsaw, Poland, Kamiñski B, Warsaw School of Economics, Warsaw, Poland, Sp_awiñski J, Drug Institute, Warsaw, Poland |
| PMH14 |
| ANTIPSYCHOTIC COMPLIANCE EVALUATION - A POPULATION-BASED, MANAGED-CARE STUDY OF PERSISTENCE WITH INITIALLY PRESCRIBED ANTIPSYCHOTIC MEDICATION
Simons WR1, Bassi R1, White R2, 1Global Health Economics and Outcomes Research, Inc, Short Hills, NJ, USA; 2AstraZeneca, Wilmington, DE, USA |
| PMH15 |
| THE IMPACT OF ALCOHOL ABUSE ON EMPLOYMENT IN SWITZERLAND
Chevrou-Severac H, Institute for Economic and Regional Research (IRER), NEUCHATEL, Switzerland |
| PMH16 |
| ATYPICAL ANTIPSYCHOTICS IN THE TREATMENT OF SCHIZOPHRENIA: ADVERSE EVENTS, NON-COMPLIANCE AND COST
Meddis D1, Williams P2, 1AstraZeneca, Macclesfield, Cheshire, UK; 2PAREXEL Medical Marketing Services, Uxbridge, UK |
| PMH17 |
| LONG-TERM ECONOMIC BENEFITS OF ANTIPSYCHOTIC USE
Boscoe AN1, White RE1, Bolge SC2, 1AstraZeneca, Wilmington, DE, USA; 2Consumer Health Sciences, Princeton, NJ, USA |
| PMH18 |
| DEPRESSION AND QUALITY OF LIFE AND THEIR EFFECT ON HEALTH CARE UTILIZATION
Bushnell DM, Martin ML, Health Research Associates Inc (HRA), Seattle, WA |
| PMH19 |
| IDENTIFICATION AND ONE-YEAR COSTS OF TREATMENT-RESISTANT DEPRESSION IN A CLAIMS DATA ANALYSIS
Corey-Lisle P1, Claxton A1, Birnbaum H2, Marynchenko M2, Greenberg P2, 1Eli Lilly and Company, Indianapolis, IN, USA; 2Analysis Group/Economics, Cambridge, MA, USA |
| PMH20 |
| COMPARISON OF ADVERSE DRUG EVENTS (ADE) ASSOCIATED WITH SELECTIVE SEROTONIN RE-UPTAKE INHIBITORS (SSRI) IN TWO MANAGED CARE ORGANIZATIONS (MCO)
Rascati KL1, Conner TM2, 1The Center for Pharmacoeconomic Studies - The University of Texas, Austin, TX, USA; 2Seton Health Network, Austin, TX, USA |
| PMH21 |
| CLINICAL AND HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WITH OLANZAPINE IN PATIENTS WITH BIPOLAR DISORDER AS COMPARED WITH HALOPERIDOL
Shi L1, Namjoshi M1, Zhang F1, Edgell E2, Tohen M1, 1Lilly Research Laboratories, Indianapolis, IN, USA; 2Lilly Research Centre, Windlesham, UK |
| PMH22 |
| QUALITY OF LIFE, SUBSTANCE USE AND RISK AND PROTECTIVE FACTORS AMONG TEENAGE WOMEN WITH INFANTS - A RANDOMIZED STUDY
Corcoran K, Portland State University, Portland, OR, USA |
| PMH23 |
| THE USE OF NEFAZODONE INTHE TREATMENT OF POST TRAUMATIC STRESS DISORDER
Voris JC1, Voris CT2, Kaltsounis J3, 1University of South Carolina, Columbia, SC, USA; 2Dorn Veterans Hospital, Columbia, SC, USA; 3Bristol-Meyers Squibb Co, New York, NY, USA |
| PMH24 |
| HEALTHCARE RESOURCE USE AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA
White RE1, Boscoe AN1, Travers J1, McDonnell DD2, 1AstraZeneca, Wilmington, DE, USA; 2Consumer Health Sciences, Princeton, NJ, USA |
| PMH25 |
| MENTAL WELL-BEING AMONG CAREGIVERS OF PEOPLE WITH SCHIZOPHRENIA
Travers J1, White RE1, Boscoe AN1, McDonnell DD2, 1AstraZeneca, Wilmington, DE, USA; 2Consumer Health Sciences, Princeton, NJ, USA |
|
|
| RESPIRATORY DISORDERS |
| PRP1 |
|
A COMPARISON OF SIX PHONE INTERVIEWS DESIGNED TO MEASURE HEALTH-RELATED LOST PRODUCTIVE TIME AT WORK
Ricci J, Stewart WF, Leotta CR, Chee E, AdvancePCS, Hunt Valley, MD, USA |
| PRP2 |
| ASTHMA MANAGEMENT AND OUTCOMES IN ITALY
Arpinelli F, Di Blasi P, Visona G, GlaxoSmithKline S.p.A, Verona, Italy |
| PRP3 |
| SPECIFIC IMMUNOTROPIC THERAPY - ASPECTS OF COST-EFFECTIVENESS
Prosekova E1, Geltzer B2, Dercach V1, Bogdanovskiy P3, 1Child's Municipal Asthma-centre, Vladivostok, Russia; 2Municipal Dalzavod Hospital, Vladivostok, Russia; 3Vladivostok State Medical University, Vladivostok, Russia |
| PRP4 |
| COST-CONSEQUENCE ANALYSIS OF TIOTROPIUM VERSUS IPRATROPIUM FOR THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Rutten-van Mölken MPMH1, Oostenbrink J2, Koch P3, 1Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, Netherlands; 2Institute for Medical Technology Assessment, Erasumus University Rotterdam, Rotterdam, Netherlands; 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany |
| PRP5 |
|
ESTIMATES OF LOST PRODUCTIVE WORK TIME ASSOCIATED WITH ALLERGIC RHINITIS (AR)
Ricci J, Stewart WF, Leotta CR, Chee E, AdvancePCS, Hunt Valley, MD, USA |
| PRP6 |
| ASMACARE STUDY. ASSESSMENT OF THE IMPACT OF AN INTERVENTION DESIGNED TO IMPROVE THE MANAGEMENT OF ASTHMA PATIENTS
Espinosa C1, Plaza V2, Molina J3, Ignacio J4, Garcia-Alonso F5, Cobos A6, 1Novartis Farmaceutica, Barcelona, Spain; 2Hospital de Sant Pau Barcelona, Barcelona, Spain; 3C.S. Francia, Fuenlabrada, Madrid, Spain; 4Hospital General Basico Serrania, Ronda. Malaga, Spain; 5Ministerio de Sanidad y Consumo, Madrid, Spain; 6RDES- Remote Data Entry System, Barcelona, Spain |
| PRP7 |
| COST-EFFECTIVENESS ANALYSIS OF SEQUENTIAL TREATMENT WITH ALMITRINE BISMESYLATE IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE
Gorecka D1, Jaworski R2, Czech M2, Pachocki R2, Corcaud S3, 1Institute of Tuberculosis and Lung Diseases, Warsaw, Poland; 2Servier Polska, Warsaw, Poland; 3Les Laboratoires Servier, Neuilly sur Seine Cedex, France |
| PRP8 |
| LIFETIME COSTS OF COPD IN THE NETHERLANDS
Feenstra T1, van Genugten ML1, Rutten-van Mölken MP2, 1National Institute of Public Health and the Environment, Bilthoven, Netherlands; 2Erasmus University Rotterdam, Rotterdam, Netherlands |
| PRP9 |
| COST-OF-ILLNESS STUDY OF PATIENTS WITH ALLERGIC ASTHMA AND SEASONAL ALLERGIC RHINITIS IN GERMANY
Quednau K1, Schramm B2, Ehlken B2, Smala A2, Naujoks C3, Berger K2, 1Novartis Pharma GmbH, Nuremberg, Germany; 2MERG - Medical Economics Research Group, Munich, Germany; 3Novartis Pharma AG, Basel, Switzerland |
| PRP10 |
| VARIATIONS IN COVERAGE FOR EFFECTIVE SERVICES FOR ASTHMA: IMPACT OF NATIONAL GUIDELINES
Hanlon JT, Wheeler J, Fendrick AM, University of Michigan, Ann Arbor, MI, USA |
| PRP11 |
|
EFFECTS OF DISEASE MANAGEMENT ON QUALITY OF LIFE IN PATIENTS WITH ASTHMA
Greiner W, Graf V.D. Schulenburg J-M, Blanke M, University of Hannover, Hannover, Germany |
| PRP12 |
| ASTHMA KNOWLEDGE AND QUALITY OF LIFE (QOL) OF ADULT ASTHMATICS
Meszaros A1, Vincze G2, Mesko A1, Orosz DM1, 1Semmelweis University, Budapest, Hungary; 2University of Texas at Austin, Austin, TX, USA |
| PRP13 |
| IMPACT OF ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN FRANCE
Duprat-Lomon I1, Mortier N1, Blin P2, Chevallier E2, Sagnier PP3, 1Bayer Pharma, Puteaux, France; 2Icare, Massy, France; 3Bayer Plc, Slough, UK |
| PRP14 |
| ASSESSING PATIENTS' PREFERENCES FOR CONVENTIONAL AND HOMEOPATHIC TREATMENT FOR ASTHMA - A CONJOINT ANALYSIS STUDY
Ratcliffe J1, Van Haselen R2, Buxton MJ3, Hardy K2, Colehan J3, Partridge M4, 1RTI Health Solutions, Manchester, UK; 2Royal London Homeopathic Hospital, London, UK; 3Brunel University, Uxbridge, UK; 4Whipps Cross Hospital, London, UK |
|
|
| OTHER HEALTH ISSUES |
| POD1 |
| ESTIMATING THE SEMI-FIXED COSTS OF A DAY-CASE EPISODE
Payne K, Elliott RA, Davies LM, University of Manchester, Manchester, UK |
| POD2 |
| USING CONTINGENT VALUATION IN A RCT FOR INDUCTION AND MAINTENANCE OF ANAESTHETIC AGENTS FOR DAY-CASE SURGERY
Elliott RA, Payne K, Davies LM, University of Manchester, Manchester, UK |
| POD3 |
| THE PSYCHOMETRIC TESTING OF THE HUNGARIAN VERSION OF THE SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRE
Lovas K1, Gergely P1, Whalley D2, Meads D2, Kalo Z3, 1Semmelweis University, Budapest, Hungary; 2Galen Research, Manchester, UK; 3Novartis Pharma AG, Basel, Switzerland |
| POD4 |
| COST-CONSEQUENCES OF ORTHOPAEDIC SURGERY IN HAEMOPHILIA PATIENTS WITH INHIBITORS
Green C, De Cock E, MEDTAP International, London, UK |
| POD5 |
| THE COST EFFECTIVENESS OF AN EXTRA-CORPOREAL LIVER ASSIST DEVICE FOR PATIENTS WITH FULMINANT HEPATIC FAILURE
Sullivan EM1, Brod M2, Maguire P3, Scott E4, 1Quintiles Late Phase, Boston, MA, USA; 2Quintiles Late Phase, San Francisco, CA, USA; 3Vitagen Inc, La Jolla, CA, USA; 4University of California at San Diego, San Diego, CA, USA |
| POD6 |
| ECONOMIC EVALUATION OF TREATING ERECTILE DYSFUNCTION IN SPAIN: THE PRIMARY CARE APPROACH VERSUS SPECIALIZED CARE
Domínguez-Gil A1, Rejas J2, Losa M3, L. Alemany JM3, Checa JC2, Palacios G2, 1Hospital Universitario de Salamanca, Salamanca, Spain; 2Pfizer S.A, Alcobendas (Madrid), Spain; 3General Trials, Madrid, Spain |
| POD7 |
| THE EF-VAS: A PREFERENCE-BASED SELF-ADMINISTRATION INSTRUMENT FOR ASSESSING THE IMPACT OF ERECTILE DYSFUNCTION (ED) AND ED TREATMENT
Torrance G1, Keresteci M2, Rosner A2, Ritvo P3, Casey R4, 1McMaster University, Innovus Research Inc, Burlington, ON, Canada; 2Innovus Research Inc, Burlington, ON, Canada; 3University of Toronto, Toronto, ON, Canada; 4Clinical Medical Excellence Research Network, Oakville, ON, Canada |
| POD8 |
| VALIDATION OF VAGINAL CONTRACEPTION ACCEPTABILITY QUESTIONNAIRE
Novak A1, Abetz L2, de la Loge C3, 1NV Organon, Oss, Netherlands; 2Mapi Values, Cheshire, UK; 3MAPI Values, Lyon, France |
| POD9 |
| AN ANALYSIS OF THE USEFULNESS AND TRANSPARENCY OF COST-EFFECTIVENESS LITERATURE FOR SURGICAL DEVICES AND PROCEDURES
Basskin LE, Chan J, Butler University College of Pharmacy and Health Sciences, Indianapolis, IN, USA |
| POD10 |
| THE BPE-PIT; AN ADAPTATION OF THE BPE-P FOR USE IN A MULTINATIONAL CLINICAL TRIAL
Eremenco SL1, Martens LL2, Harris R1, Arnold B1, MacDonagh R3, 1Evanston Northwestern Healthcare, Evanston, IL, USA; 2R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ, USA; 3Taunton and Somerset Hospital, Taunton, Somerset, UK |
| POD11 |
| BENIGN PROSTATIC HYPERPLASIA: CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE: RISK OF SOMNOLENCE
Perrin P1, Levy E2, Smadja C3, Taïeb C3, 1Hopital de l'Antiquaille, Lyon, France; 2University Paris-Dauphine, Paris, France; 3bioMérieux-Pierre Fabre, Boulogne Billancourt, France |
| POD12 |
| BENIGN PROSTATIC HYPERPLASIA: RECOGNITION OF THE CONSEQUENCES OF THE PATHOLOGY FOR THE SPOUSE
Levy E1, Perrin P2, Smadja C3, Peroud Gassan V4, Taïeb C3, 1University Paris-Dauphine, Paris, France; 2Hopital de l'Antiquaille, Lyon, France; 3bioMérieux-Pierre Fabre, Boulogne Billancourt, France; 4Pierre Fabre Médicament, Castres, France |
| POD13 |
| A RISK-ASSESSMENT MODEL FOR ERECTILE DYSFUNCTION: THE SEXUAL-HEALTH INVENTORY FOR MEN AND RELATED MEDICAL CONDITIONS
Ambegaonkar AJ1, Gao X2, Day DL1, Herriott KB1, 1Pfizer Inc, New York, NY, USA; 2PPD Development, Morrisville, NC, USA |
| POD14 |
| COST-EFFECTIVENESS ANALYSIS OF THE SPECTRON VERSUS CHARNLEY HIP PROSTHESES
Briggs AH1, Sculpher MJ2, Dawson J3, Malchau H4, 1University of Oxford, Oxford, UK; 2York University, York, UK; 3Oxford Brookes University, Oxford, UK; 4Göteborg University, Göteborg, Sweden |
|
